GENESIS REFERENCE LABORATORIES LLC NPI 1982091617

NPI Details

GENESIS REFERENCE LABORATORIES, LLC is a clinical medical laboratory in Orlando, FL. The provider is (1) A clinical laboratory is a facility for the biological, microbiological, serological, chemical, immunohematological, hematological, biophysical, cytological, pathological, or other examination of materials derived from the human body for the purpose of providing information for the diagnosis, prevention, or treatment of any disease or impairment of, human beings. These examinations also include procedures to determine, measure, or otherwise describe the presence or absence of various substances or organisms in the body. Facilities only collecting or preparing specimens (or both) or only serving as a mailing service and not performing testing are not considered clinical laboratories. (2) Any facility that examines materials from the human body for purposes of providing information for the diagnosis, prevention, or treatment of any disease or impairment of, or the assessment of, the health of human beings. Typical divisions of a clinical laboratory include hematology, cytology, bacteriology, histology, biochemistry, medical toxicology, and serology. GENESIS REFERENCE LABORATORIES, LLC NPI is 1982091617. The provider is registered as an organization entity type.

The provider's business location address is:

7924 FOREST CITY RD STE 210
ORLANDO, FL
ZIP 32810-925
Phone: (407) 232-7172
Fax: (407) 289-4082

The provider's authorized official is Philip David Freitas .
The authorized official title is Managing Member and has the following contact phone number (407) 232-7172.

The CLIA number assigned to this NPI record is 10D2102433 - independent with a certificate type of Certificate of Accreditation.

The following top HCPCS codes were publicly reported for this provider under the Medicare program for the year 2016. The reported codes are based on the top codes for each available Medicare specialty, excluding evaluation and management codes.

• 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r (HCPCS:U0004)
• Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within (HCPCS:U0005)
• Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]) from an individual in a snf or by a laboratory on behalf of a hha, any specimen source (HCPCS:G2024)
• Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (HCPCS:G0482)
• Detection test by nucleic acid for organism, amplified probe technique (HCPCS:87798)
• Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (HCPCS:G0483)
• Testing for presence of drug, by chemistry analyzers (HCPCS:80307)
• Detection test by nucleic acid for staphylococcus aureus (bacteria), amplified probe technique (HCPCS:87640)
• Detection test for candida species (yeast), amplified probe technique (HCPCS:87481)
• Detection test by nucleic acid for strep (streptococcus, group b), amplified probe technique (HCPCS:87653)
• Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (HCPCS:G0481)
• Identification of organisms by genetic analysis, amplified probe technique (HCPCS:87150)
• Detection test by nucleic acid for vancomycin resistance strep (vre), amplified probe technique (HCPCS:87500)
• Detection test by nucleic acid for chlamydia pneumoniae, amplified probe technique (HCPCS:87486)
• Detection test by nucleic acid for mycoplasma pneumoniae (bacteria), amplified probe technique (HCPCS:87581)
• Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (HCPCS:G0480)
• Detection test by multiplex amplified probe technique for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (covid-19) and influenza virus types a and b (HCPCS:87636)
• Detection test by nucleic acid for trichomonas vaginalis (genital parasite), amplified probe technique (HCPCS:87661)
• Detection test by nucleic acid for neisseria gonorrhoeae (gonorrhoeae bacteria), amplified probe technique (HCPCS:87591)
• Detection test by nucleic acid for chlamydia trachomatis, amplified probe technique (HCPCS:87491)
• Detection of mycoplasma genitalium by dna or rna probe (HCPCS:87563)
• Detection test by nucleic acid for digestive tract pathogen, multiple types or subtypes, 12-25 targets (HCPCS:87507)

The enumeration date for this NPI number is 4/21/2015 and was last updated on 5/16/2019.

Taxonomy Codes

The NPI record includes the healthcare provider taxonomy classification, state license number and state of licensure. The following information regarding the scope of practice of this provider is available: